Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus KEFTAB.
CEFTRIAXONE IN PLASTIC CONTAINER vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic